Published in Cancer Weekly, February 20th, 1995
All three patients have received transfers of at least 1 billion cells, and two have received transfers of 10 billion cells. In all, 12 patients are enrolled in the Phase I study, reported University of Michigan researcher Gary Nabel at the 2nd National Conference on Human Retroviruses and Related Infections, held January 29-February 2, 1995, in Washington, D.C.
The Rev M10 construct is one of three anti-HIV gene therapy strategies currently in Phase I clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.